Iris Biotechnologies (IRSB)

Iris Biotechnologies, Inc. was incorporated on February 16, 1999 under the laws of the State of California. The Company is engaged in personalized and targeted medicine, focusing on enabling the right medical treatment for the right person at the right time. The Company has five patents granted in the United States and some of those are already granted in Canada, Europe, Asia, New Zealand and Australia. The Iris Nano-biochip is a special silicon chip that enables physicians to identify and analyze the DNA's gene expression profile involved in a disease. The Company has an extensive pipeline of disease chips, including a BreastCancerChip, ColonCancerChip, NeuroChip, Comprehensive CancerChip, CardioChip, and MetabolicChip; however, with initial efforts on helping breast cancer patients. The QTDP grant provided recognition of the Company's patented Nano-Biochip and BioWindows Medical Informatics System for optimizing personalized and targeted medical treatment. The Company is a life sciences company preparing for multiple product launches in the field of personalized medicine. The Company conducts tests by using a 100+ gene expression test with additional genomic, proteomic, personal lifestyle, family medical history, and environmental exposure information to optimize longevity and quality of life. The Iris BioWindows Informatics System for Personalized and Targeted Medicine handles the analysis of the gene expression and genetic variation data as well as protein and other biomarker information collected by the Nano-Biochip. BioWindows is an artificial intelligence system, which includes a powerful database with molecular signatures, in-depth patient demographics and lifestyle information, family medical histories and treatment-response profiles for many diseases. The Company's nano-biochip technology platform was developed using a convergence of scientific disciplines in nanotechnology, semiconductor manufacturing, microfluidics, chemistry, molecular biology, genetics, genomics, and information technology. BioWindows database comprises data fields for patient demographic information, personal medical history, family medical history, and gene expression information for storing actual patient information. With its manufacturing system, the Company plans to build medical products such as the BreastCancerChip, ColonCancerChipä, Comprehensive Cancer Chip, NeuroChip, CardioChip, and MetabolicChip, as well as chips for other applications including veterinary, agricultural and environmental problems. It intends to use its BioWindows database to enable drug development, stem cell research, and evolving clinical applications. The Company's silicon bishop gene detection platform consists of proprietary technologies incorporated into oligonucleotide and PNA chips, customized readers/scanners and BioWindows genetic information interpretation system.